Table 4.
Factors associated with overall survival
| Univariate Analysis | Multivariable Analysis | |||
|---|---|---|---|---|
|
| ||||
| Hazard Ratio | 95% CI | Hazard Ratio | 95% CI | |
|
| ||||
| Race/Ethnicity | ||||
| White | Reference | Reference | Reference | Reference |
| Hispanic | 1.07 | 0.78 – 1.50 | 0.83 | 0.74 – 0.94 |
| Black | 1.34 | 1.11 – 1.61 | 1.12 | 1.10 – 1.14 |
|
| ||||
| Type of medical coverage | ||||
| Commercial | Reference | Reference | Reference | Reference |
| Medicare | 0.99 | 0.51 – 1.94 | 0.87 | 0.51 – 1.49 |
| Medicaid | 1.51 | 1.24 – 1.84 | 0.79 | 0.73 – 0.85 |
| Financial Assistance | 1.99 | 1.51 – 2.62 | 0.96 | 0.86 – 1.08 |
| Other | 1.20 | 0.87 – 1.65 | 0.83 | 0.80 – 0.87 |
|
| ||||
| Child Pugh Class | ||||
| Child Pugh A | Reference | Reference | Reference | Reference |
| Child Pugh B | 1.99 | 1.70 – 2.34 | 1.52 | 1.36 – 1.70 |
| Child Pugh B | 3.39 | 1.50 – 7.64 | 0.89 | 0.64 – 1.24 |
|
| ||||
| BCLC stage | ||||
| Stage 0/A | Reference | Reference | Reference | Reference |
| Stage B | 2.39 | 2.26 – 2.54 | 1.79 | 1.79 – 1.80 |
| Stage C | 6.19 | 4.38 – 8.74 | 3.22 | 2.06 – 5.04 |
| Stage D | 6.39 | 2.80 – 14.57 | 4.34 | 3.45 – 5.45 |
|
| ||||
| Treatment | ||||
| Liver transplantation | Reference | Reference | Reference | Reference |
| Resection | 3.30 | 2.47 – 4.41 | 5.40 | 3.87 – 7.53 |
| Local ablation | 5.56 | 5.45 – 5.68 | 7.98 | 5.65 – 11.3 |
| TACE/TARE/SBRT | 10.8 | 7.03 – 16.6 | 11.10 | 5.82 – 21.2 |
| Systemic therapy | 31.2 | 16.2 – 60.3 | 16.9 | 12.0 – 23.9 |
| Best supportive care | 47.8 | 22.8 – 100.3 | 31.3 | 17.9 – 54.7 |
BCLC – Barcelona Clinic Liver Cancer; SBRT – stereotactic body radiation therapy; TACE – transarterial chemoembolization; TARE – transarterial radioembolization